{"id":45291,"date":"2025-10-30T17:04:14","date_gmt":"2025-10-30T09:04:14","guid":{"rendered":"https:\/\/flcube.com\/?p=45291"},"modified":"2025-10-30T17:04:14","modified_gmt":"2025-10-30T09:04:14","slug":"bayer-sells-avelox-moxifloxacin-business-to-hsg-for-up-to-e260-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45291","title":{"rendered":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion"},"content":{"rendered":"\n<p><strong>Bayer AG (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>)<\/strong> announced that it has entered into a Share Purchase Agreement (SPA) with <strong>HSG<\/strong> (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic <strong>Avelox (moxifloxacin)<\/strong>. The transaction is valued at <strong>\u20ac160\u202fmillion to \u20ac260\u202fmillion<\/strong> (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-highlights\"><strong>Deal Highlights<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Fit<\/strong> \u2013 Avelox, historically a core product in China\u2019s volume\u2011based procurement (VBP) program, is deemed a non\u2011core asset under Bayer\u2019s \u201cdivestment of mature brands\u201d strategy.<\/li>\n\n\n\n<li><strong>Financial Impact<\/strong> \u2013 The sale will provide Bayer with a cash injection to support its portfolio shift toward high\u2011growth, high\u2011margin therapeutics.<\/li>\n\n\n\n<li><strong>Timing<\/strong> \u2013 The SPA was signed in the second quarter of 2025; HSG has yet to confirm the transaction publicly.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\"><strong>Market Context<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Moxifloxacin Sales<\/strong> \u2013 Bayer did not disclose 2025 interim sales for Avelox, reflecting its declining commercial relevance.<\/li>\n\n\n\n<li><strong>China\u2019s VBP Dynamics<\/strong> \u2013 The drug\u2019s prior inclusion in VBP batches underscores its historical importance; the divestiture signals a broader shift away from legacy antibiotics in the Chinese market.<\/li>\n\n\n\n<li><strong>HSG\u2019s Position<\/strong> \u2013 As a former Sequoia Capital China vehicle, HSG is positioned to acquire and potentially reposition the asset within its broader pharmaceutical portfolio.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45292,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[269,967],"class_list":["post-45291","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bayer","tag-etr-bayn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA) with HSG (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic Avelox (moxifloxacin). The transaction is valued at \u20ac160\u202fmillion to \u20ac260\u202fmillion (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45291\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA) with HSG (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic Avelox (moxifloxacin). The transaction is valued at \u20ac160\u202fmillion to \u20ac260\u202fmillion (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45291\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T09:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion\",\"datePublished\":\"2025-10-30T09:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291\"},\"wordCount\":222,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3009.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45291#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45291\",\"name\":\"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3009.webp\",\"datePublished\":\"2025-10-30T09:04:14+00:00\",\"description\":\"Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA) with HSG (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic Avelox (moxifloxacin). The transaction is valued at \u20ac160\u202fmillion to \u20ac260\u202fmillion (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45291\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3009.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3009.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45291#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA) with HSG (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic Avelox (moxifloxacin). The transaction is valued at \u20ac160\u202fmillion to \u20ac260\u202fmillion (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45291","og_locale":"en_US","og_type":"article","og_title":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion","og_description":"Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA) with HSG (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic Avelox (moxifloxacin). The transaction is valued at \u20ac160\u202fmillion to \u20ac260\u202fmillion (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).","og_url":"https:\/\/flcube.com\/?p=45291","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T09:04:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45291#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45291"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion","datePublished":"2025-10-30T09:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45291"},"wordCount":222,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45291#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp","keywords":["Bayer","ETR: BAYN"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45291#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45291","url":"https:\/\/flcube.com\/?p=45291","name":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45291#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45291#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp","datePublished":"2025-10-30T09:04:14+00:00","description":"Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA) with HSG (formerly Sequoia Capital China) to divest the assets and business related to its fluoroquinolone antibiotic Avelox (moxifloxacin). The transaction is valued at \u20ac160\u202fmillion to \u20ac260\u202fmillion (\u2248\u202f\u00a51.32\u202fbillion to \u00a52.15\u202fbillion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45291#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45291"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45291#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp","width":1080,"height":608,"caption":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45291#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to \u20ac260\u202fMillion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3009.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45291"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45291\/revisions"}],"predecessor-version":[{"id":45293,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45291\/revisions\/45293"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45292"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}